Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared a post on X about a paper he co-authored with colleagues published in The Oncologist:
“HRQoL in early-stage NSCLC is still underreported.
Current QoL tools lack granularity in domains as sleep and sexual life.
Assessment timeframes may fail to capture late/chronic QoL effects occurring, especially with ICI, after treatment ends.”
Cecilia Pompili, Associate Professor and Thoracic Surgeon focusing on Patient Reported Outcomes Research at the University of Hull, shared this post, adding:
“A special thank you to Fabio Salomone and Giorgia Novero – such a detailed and thoughtful analysis in a field as heterogeneous and still insufficiently standardised as QoL assessment.”
Title: Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoint inhibitors in early-stage NSCLC
Authors: Fabio Salomone, Giorgia Novero, Oriana Ciani, Roberto Ferrara, Alberto Servetto, Narjust Florez, Massimo Di Maio, Gabriella Pravettoni, Cecilia Pompili
You can read the Full Article in The Oncologist.
More posts featuring Roberto Ferrara.
